Physicians' Academy for Cardiovascular Education
Member

Understanding BET inhibition as a novel pathway for cardiovascular risk modulation

Aug. 28, 2016 - ESC 2016, Rome - Jorge Plutzky, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA - Recorded at PACE-CME symposium at ESC 2016

This lecture was part of a CME accredited symposium: 'A novel approach for high CV risk patients with diabetes: The potential of epigenetics' held at ESC 2016 in Rome

Educational information

The educational objectives of this symposium were:

CME accreditation

This programme is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit(s).

Faculty & Disclosures

Jorge Plutzky, M.D. is the Director of the Vascular Disease Prevention Program, which includes the Lipid/Prevention Clinic, at Brigham and Women’s Hospital (BWH), and is on the faculty of Harvard Medical School

Funding

Supported by an unrestricted educational grant from Resverlogix